Get in on the ground floor as we look at the most exciting crowdfunded tech projects out there right now. This week: Technical Illusions' castAR is a 3D, holographically projecting generator that lets you position objects in virtual space. Key add-ons include a magic wand, which acts as a controller and is also tracked; and an RFID grid that underlies the system's reflective surface.
Do you remember the scene in an early Star Wars movie where R2-D2 and Chewbacca played a holographically generated, Jedi 3D board game while killing time in their light freighter? Full-color, three-dimensional game pieces were projected onto the board. Chewbacca wasn't a particularly good loser, and R2-DR2 blipped and beeped a lot.
Well, a few decades later, we may be about to see a projected augmented reality system -- for real. Kickstarter project castAR is a 3D, holographically projecting generator that lets you position objects in virtual space. Applications include gaming.
How it Works
A pair of glasses are equipped with two projectors, one over each eye. The projectors create a 3D view onto a highly reflective surface.
A tracking camera, installed in the glasses, picks up identification markers embedded on the reflective surface.
The reflective surface is designed to reduce scattering of light, enabling multiple players to see the projections, and the camera lets software track the player's head in relation to the physical scene. Software then portrays the projected scene.
The Add-ons
Key add-ons to castAR include a magic wand, which acts as a controller and is also tracked; a radio-frequency identification, or RFID, grid that underlies the reflective surface, along with RFID bases that can be attached to existing miniature game pieces; and a non-projection virtual reality, or VR, and non-projection augmented reality, or AR, clip-on glasses attachment.
The difference between AR and VR is that AR includes a view of the real world too, not just a totally fabricated virtual world, as is the case with VR.
Technical Details
The creator reckons that the glasses will ultimately weigh less than 100 grams and will fit over prescription glasses if necessary. The in-glasses camera detects movements to the sub-millimeter and only processes the image and analyzes it, sending results to the PC, thus reducing processor requirements for the PC.
One version of the optional RFID existing miniature bases can track and provide two-way communication for miniature electronics, like future-developed motors.
The Numbers
Technical Illusions currently has roughly 1,500 backers for castAR who are contributing more than US$350,000 of a $400,000 goal. The funding period ends on Nov. 14.
A contribution of $189 gets you the starter package, including the glasses and a one-meter by one-meter reflective surface. A $395 contribution gets you a two-player gaming set-up, with two magic wands and the larger one-meter by two-meter surface.
The estimated shipping date is September 2014.
The Upsides
From a crowdfunding, jump-in perspective, we like the fact that this potential product is self-contained and not dependent on other technology becoming ready. As a counter-example, the Oculus Rift virtual reality headset -- thus far only available to developers -- is also spurring crowdsourced add-ons, like the Transporter3D telepresence add-on.
castAR could be a more tangible project to get involved in.
Undoubtedly this genre of gaming device -- the immersive virtual and augmented environment -- is just waiting to explode onto the gaming market.
We think that it's going to be a question of who can combat latency, required-processing power, physical size and weight issues, and VR-induced nausea.
AR, which includes the physical world, has the advantage that it's less likely to cause seasickness-like nausea, a common side-effect with all-immersing VR that's created by the body and brain getting discombobulated.
castAR, in its native form, is a projected form of AR that may well get the combination of real-world and virtual correctly mixed.
The Downsides
This is a rapidly developing area and a number of devices may come to market at the roughly same time. They include VR goggles a la Oculus Rift; retina projectors that don't use screens at all; elaborate telepresence 2D and 3D processors for VR goggles; and this, the castAR holographic projector.
It will be the gamers who decide who wins this battle for the next generation of game interfaces.
Patrick Nelson has been a professional writer since 1992. He was editor and publisher of the music industry trade publication Producer Report and has written for a number of technology blogs. Nelson studied design at Hornsey Art School and wrote the cult-classic novel Sprawlism. His introduction to technology was as a nomadic talent scout in the eighties, where regular scrabbling around under hotel room beds was necessary to connect modems with alligator clips to hotel telephone wiring to get a fax out. He tasted down and dirty technology, and never looked back.
AT&T senior vice president Chris Penrose announced a new $5 day pass for data at the GigaOm Mobilize conference in San Francisco today, with hopes that it'll compete against expensive hotel WiFi for frequent travelers. The day pass is limited to just 250MB of data however. You can also opt for a $25 ...
NEW YORK (AP) — Like the character he plays, Clark Gregg has worked his way up the career ladder.
Five years ago, he played Agent Phil Coulson for the first time as a small role in the Robert Downey Jr. romp "Iron Man."
Now, after gaining an ever-higher profile as Coulson in subsequent projects including last year's mega-hit "The Avengers," Gregg has broken out as the star of "Marvel's Agents of S.H.I.E.L.D.," the new acronymic sci-fi thriller (airing on ABC Tuesdays at 8 p.m. EDT), which finds Coulson leading a hand-picked band of agents on their extra-special missions.
Gregg's own mission: to savor his spot as No. 1 on the "Marvel's Agents" call sheet after years of diverse, solid and often acclaimed work that, nonetheless, fell short of making him a household name.
Gregg, 51, has earned his new prominence. As Coulson, he projects a mild demeanor (except when he doesn't) and a boyish smile (except when he takes dead-aim with his weapon or busts a bad guy in the chops). He's a tangy blend of milquetoast and steel.
And he looks good, though not too good, in his habitual company-man business suit.
"Coulson never takes his suit off," said executive producer Maurissa Tancharoen, speaking from Los Angeles, "whether he's on the beach, in the jungle ..."
"But at the risk of spoilers," stepped in fellow exec producer Jed Whedon, "you will see him in a future episode — sans tie!"
Agent Coulson is also a master of the dry quip, courtesy of Gregg.
"No matter what the line, Clark always makes it sound so classy and cool," said Tancharoen.
"The show doesn't take itself too seriously," Gregg notes gratefully during a recent chat in New York, "except in the moments when it needs to. The rest of the time it has a real sense of humor. 'I'm going to Taser you and watch "Supernanny" while you drool into the carpet': That's just not the kind of line I've gotten playing an agent in something else," like, for instance, "The West Wing," where he had a recurring role as, yes, an FBI special agent.
It should come as no surprise that Gregg has a gift for comedy. From 2006 to 2010 he played the mild-mannered but flighty ex-husband of Julia Louis-Dreyfus on her CBS sitcom, "The New Adventures of Old Christine."
Now he gets to lead a team of sexy operatives from the (wait for it) Strategic Homeland Intervention Enforcement and Logistics Division who investigate the extra-normal and superhuman people infesting their futuristic world.
Like "The Avengers," ''Marvel's Agents" boasts a comic-book soul and the creative mojo of Joss (brother of Jed) Whedon. Rounding out its cast are Brett Dalton, Ming-Na Wen, Iain De Caestecker, Elizabeth Henstridge and Chloe Bennet as Coulson's team.
"Coulson loves his job," says Gregg. "He's jaded, he's seen too much, but he can really geek out. You could imagine him doing selfies with crazy alien corpses! I'm making that up, but he's WAY into what he does."
So is Gregg.
"This show depicts a world that I loved as a kid," says Gregg, whose comic-book faves were Iron Fist, a Kung Fu superhero, and Adam Warlock, an artificial human built by scientists. "This show has given me a great chance to take my 13-year-old self to work with me every day."
Gregg has covered a great distance to get there. He studied drama at New York University's Tisch School of the Arts, where playwright David Mamet and actor William H. Macy were his teachers.
He later joined them to form New York's respected Atlantic Theater Company. He has written screenplays, including the 2000 Harrison Ford fright drama "What Lies Beneath." He has directed two films from his own screenplays, with his dark comedy "Trust Me" set for release next year.
Along the way, Gregg met actress Jennifer Grey.
"The universe threw us at each other a number of times," he says with a laugh, "but all our attempts at flirting nearly ended up in fistfights. Then, after four years of that, finally something clicked."
They wed in 2001.
When he first took on the role of Coulson, Gregg saw comics-bred cinema as a breed apart from the dramatic work he had done.
"I had worked with Mamet, Macy, ('West Wing' mastermind Aaron) Sorkin! I thought this would be different, that it would be slumming in a pop-culture world."
He now eschews such snobbery.
"When I see the connection that this kind of project has made with people on a global level, I realize that's what I got into acting for," he says. "I don't think there's a higher, more highbrow goal to hope for. After all, Shakespeare wasn't doing work for the queen, he was writing for a bunch of people chewing on disgusting sausages and talking back to the stage."
Gregg laughs and effects an apologetic air. "I don't mean to retroactively trash the sausage vendors of Elizabethan England!" he says. "I just destroyed their Yelp rating."
___
EDITOR'S NOTE — Frazier Moore is a national television columnist for The Associated Press. He can be reached at fmoore@ap.org and at http://www.twitter.com/tvfrazier .
Social shopping and deals-focused startup Shopcade, which launched out of the U.K. in November 2011, has raised £2.5 million (circa $4 million) to accelerate its growth on mobile. Investors in the funding round include Pascal Cagni, formerly head of Apple’s European business from 2000 to 2012, and Michel Combes, CEO of telecommunications company Alcatel-Lucent and ex-CEO of Vodafone Europe.
First order of business for Shopcade’s mobile push: expanding its app portfolio. Shopcade doesn’t currently have an Android app — but will be launching one next month, along with a refreshed-for-iOS-7 iOS app.
Shopcade’s ecommerce platform hosts products from more than 16,000 retailers and over 150,000 brands — with a focus on fashion, clothes and accessories but also incorporating other product categories such as books, media and electronics.
Its primary target is young females but it isn’t excluding men either…
The current Shopcade app lets users keep tabs on items they want to buy, informing them when something on their list goes on sale. It also pushes out personalised recommendations, and lets users follow each other to style stalk trendsetters (aka other users whose style they dig). Users can add items to their Shopcade list from any website, not just the items Shopcade hosts.
This year it’s been focused on expanding its deals segment, introducing deals that are specifically tied to items users have added to their wish lists. Another focus has been on outreach: in June it launched a widget targeting fashion bloggers and publishers, allowing them to embed a showcase of product picks — or auto-populated products related to page contents — in a grid or carousel.
It’s also pushed into celebrity tie-ups, by allowing its users to have the chance to style a celebrity look under its ‘Stylist for a Day’ campaign.
Going forward, Shopcade evidently sees big data as its bread and butter, based on the intel it’s continually gathering about fashion-focused shoppers’ likes (and by implication dislikes) — and then selling that ‘trend spotting’ business intelligence back to large retailers so they can decide what to stock on their shelves.
Shopcade’s expansion into widgets helps with that, allowing it to cosy up to other fashion-focused communities. Mobile is another key data point to this big data play, furnishing Shopcade with more up-to-the-minute data on what its users are after.
As an example of the kind of trends it’s apparently able to call, Evan Adelman, Shopcade CTO, said funny pet costumes started to trend on the platform ahead of Halloween — and crucially ahead of marketing spending for Halloween — adding that the category is now highlighted on Amazon.com.
Commenting on the funding round in a statement, Pascal Cagni added: ”By identifying the game-changing opportunities in mobile commerce, Shopcade is set to become the leading mobile shopping platform targeting fashionable young females audience.”
Prior angel investors in Shopcade include Daniel Bernard, former CEO of European retailer Carrefour; Ian Livingston, co-founder of Eidos Games; and Lord John Birt, former director general of the BBC.
Vaccine confers long-term protection against cholera
PUBLIC RELEASE DATE:
16-Oct-2013
[
| E-mail
| Share
]
Contact: Tae Kyung Byun tkbyun@ivi.int 82-119-773-6071 International Vaccine Institute
First time an oral cholera vaccine is proven to provide sustained protection for five years against cholera
A clinical study published in the Lancet Infectious Diseases shows for the first time that an oral cholera vaccine (ShancholTM) provides sustained protection against cholera in humans for up to five years. The study showed the vaccine had a protective efficacy of 65% over a five-year period. The landmark study was a collaboration between scientists from the International Vaccine Institute (IVI) an international organization based in Seoul, and the National Institute of Cholera and Enteric Diseases, (NICED), an institute under the Indian Council of Medical Research (ICMR) of India's Ministry of Health and Family Welfare.
Cholera is a potentially deadly infectious disease that causes profuse, dehydrating diarrhea in children and adults. It is spread through ingestion of contaminated water or food and is commonly found in developing countries that have limited access to clean water and sanitation. There are about 2.8 million cases and 91,000 deaths each year from cholera, mostly in Africa and South Asia.
The oral cholera vaccine (OCV) contains strains of killed cholera bacteria that have been previously shown to be safe in humans and is administered through a two-dose regimen. The vaccine was specifically developed for use in developing countries through a public-private partnership led by IVI with support from the Republic of Korea, Sweden, and the Bill & Melinda Gates Foundation. The partnership involved Shantha Biotechnics (part of the Sanofi group) based in Hyderabad, India; VaBiotech, a state-owned vaccine manufacturer located in Hanoi, Vietnam; and the University of Gothenburg in Sweden. The vaccine, which is produced by Shantha Biotechnics in India and licensed as Shanchol, was prequalified by the World Health Organization (WHO) in September 2011.
A Phase III clinical trial was jointly conducted by IVI and NICED in Kolkata, India in 2006 to assess the efficacy of the vaccine. More than 30,000 volunteers from one year old and up were enrolled in the study. A placebo group with a similar number of volunteers was also included.
Previous results from this study had shown that the vaccine provided 66% protection over a three-year period, and the new result shows that such protection is sustained for two additional years. Since vaccine protection does not wane over time, the study has important practical implications in terms of vaccination cost and vaccination strategies in developing countries.
"The study results suggest that this vaccine will protect persons at risk of severe cholera for five years," said Dr. Thomas F. Wierzba, Deputy Director General of Vaccine Development & Delivery at IVI and co-author of the study. "With protection sustained for five years, we will be able to provide greater benefits to the poor at reduced costs."
Furthermore, the study confirms the use of the vaccine as a powerful and effective tool to prevent and control cholera. "The vaccine is safe, easy to administer, cost effective, and provides protection for up to five years," said Dr. Christian Loucq, IVI's Director General. "The use of the vaccine, combined with other control measures, will make it more feasible for developing countries afflicted by cholera to control a disease that plagues millions of people every year."
The vaccine has already been used to combat outbreaks in Haiti and Guinea, and has been deployed for large-scale use in Bangladesh and Odisha state, India.
###
About IVI
The International Vaccine Institute (IVI) is the world's only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world's poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit http://www.ivi.int.
[
| E-mail
| Share
]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Vaccine confers long-term protection against cholera
PUBLIC RELEASE DATE:
16-Oct-2013
[
| E-mail
| Share
]
Contact: Tae Kyung Byun tkbyun@ivi.int 82-119-773-6071 International Vaccine Institute
First time an oral cholera vaccine is proven to provide sustained protection for five years against cholera
A clinical study published in the Lancet Infectious Diseases shows for the first time that an oral cholera vaccine (ShancholTM) provides sustained protection against cholera in humans for up to five years. The study showed the vaccine had a protective efficacy of 65% over a five-year period. The landmark study was a collaboration between scientists from the International Vaccine Institute (IVI) an international organization based in Seoul, and the National Institute of Cholera and Enteric Diseases, (NICED), an institute under the Indian Council of Medical Research (ICMR) of India's Ministry of Health and Family Welfare.
Cholera is a potentially deadly infectious disease that causes profuse, dehydrating diarrhea in children and adults. It is spread through ingestion of contaminated water or food and is commonly found in developing countries that have limited access to clean water and sanitation. There are about 2.8 million cases and 91,000 deaths each year from cholera, mostly in Africa and South Asia.
The oral cholera vaccine (OCV) contains strains of killed cholera bacteria that have been previously shown to be safe in humans and is administered through a two-dose regimen. The vaccine was specifically developed for use in developing countries through a public-private partnership led by IVI with support from the Republic of Korea, Sweden, and the Bill & Melinda Gates Foundation. The partnership involved Shantha Biotechnics (part of the Sanofi group) based in Hyderabad, India; VaBiotech, a state-owned vaccine manufacturer located in Hanoi, Vietnam; and the University of Gothenburg in Sweden. The vaccine, which is produced by Shantha Biotechnics in India and licensed as Shanchol, was prequalified by the World Health Organization (WHO) in September 2011.
A Phase III clinical trial was jointly conducted by IVI and NICED in Kolkata, India in 2006 to assess the efficacy of the vaccine. More than 30,000 volunteers from one year old and up were enrolled in the study. A placebo group with a similar number of volunteers was also included.
Previous results from this study had shown that the vaccine provided 66% protection over a three-year period, and the new result shows that such protection is sustained for two additional years. Since vaccine protection does not wane over time, the study has important practical implications in terms of vaccination cost and vaccination strategies in developing countries.
"The study results suggest that this vaccine will protect persons at risk of severe cholera for five years," said Dr. Thomas F. Wierzba, Deputy Director General of Vaccine Development & Delivery at IVI and co-author of the study. "With protection sustained for five years, we will be able to provide greater benefits to the poor at reduced costs."
Furthermore, the study confirms the use of the vaccine as a powerful and effective tool to prevent and control cholera. "The vaccine is safe, easy to administer, cost effective, and provides protection for up to five years," said Dr. Christian Loucq, IVI's Director General. "The use of the vaccine, combined with other control measures, will make it more feasible for developing countries afflicted by cholera to control a disease that plagues millions of people every year."
The vaccine has already been used to combat outbreaks in Haiti and Guinea, and has been deployed for large-scale use in Bangladesh and Odisha state, India.
###
About IVI
The International Vaccine Institute (IVI) is the world's only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world's poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 20 countries of Asia, Africa and Latin America on vaccines against enteric and diarrheal infections, Japanese encephalitis, and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit http://www.ivi.int.
[
| E-mail
| Share
]
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.